<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04212273</url>
  </required_header>
  <id_info>
    <org_study_id>drjingxiang001</org_study_id>
    <nct_id>NCT04212273</nct_id>
  </id_info>
  <brief_title>Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC</brief_title>
  <official_title>A Single-center, Prospective Controlled Study of the Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Third Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Third Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is the fifth most common cancer. Patients with HCCs usually
      have a poor prognosis. Hepatocarcinogenesis is an intricate and multistep process. Detecting
      and staging early HCC in patients with liver cirrhosis are still challenging for imaging
      techniques. Contrast-enhanced ultrasonography (CEUS) and gadoxetic acid-enhanced magnetic
      resonance imaging (EOB-MRI) are widely used in clinical practice. EOB-MRI has advantages of
      high detecting rate for small lesions, high sensitivity of hepatobiliary phase and extensive
      image information. Sonazoid has the advantage of offering a unique post-vascular phase, also
      called the Kupffer phase. Therefore, malignant tumors with few or no Kupffer cells appear as
      contrast defects, with respect to the relatively well-enhanced surrounding liver in the
      postvascular phase. The diagnostic efficacies of these two imaging methods have not been well
      studied. Therefore, the purpose of this study is to compare the efficacies of Sonazoid-CEUS
      and EOB-MRI in patients with high risk of HCC, and to compare the detection ability for
      malignant tumors by Kupffer phase and hepatobiliary phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 24, 2019</start_date>
  <completion_date type="Anticipated">December 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The sensitivity, specificity and accuracy of Sonazoid-CEUS and EOB-MRI</measure>
    <time_frame>6 to 12 months</time_frame>
    <description>The sensitivity, specificity and accuracy of Sonazoid-CEUS and EOB-MRI in the diagnosis for patients with high risk of HCC will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The detection rate of the additionally found HCC</measure>
    <time_frame>6 to 12 months</time_frame>
    <description>The detection rate of the additionally found HCC on Sonazoid-CEUS and EOB-MRI will be determined .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatocellular Cancer</condition>
  <condition>Liver Cirrhoses</condition>
  <condition>Diagnoses Disease</condition>
  <arm_group>
    <arm_group_label>Diagnostic Sonazoid-CEUS and EOB-MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with high risk of HCC having suspicious lesions on US will receive Sonazoid-CEUS and EOB-MRI examinations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic Sonazoid-CEUS and EOB-MRI</intervention_name>
    <description>Undergo Sonazoid-CEUS and EOB-MRI</description>
    <arm_group_label>Diagnostic Sonazoid-CEUS and EOB-MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients are at high risk for HCC.

          2. The ages of patients are between 18 and 80.

          3. Patients are with solid liver lesion(s) detected by US: if a patient has a solitary
             tumor, the size of the tumor is less than or equal to 5 cm; if a patient has multiple
             lesions, the sizes of the tumors are less than or equal to 3 cm and the number of
             lesions is less than or equal to 3.

          4. Patient is able and willing to receive CEUS and EOB-MRI examinations within 30 days.

          5. Patient signs the informed consent. -

        Exclusion Criteria:

          1. Patient is with lesions confirmed by pathology or follow-up, or hemangiomas.

          2. Patient is with lesions already undergoing local treatment, including thermal ablation
             or TACE.

          3. Patient is with severe cardiopulmonary insufficiency.

          4. Patient is a pregnant or breastfeeding women.

          5. Patient is considered to be unsuitable to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Jing, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tianjin Third Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Jing, MD</last_name>
    <phone>02284112323</phone>
    <phone_ext>+86</phone_ext>
    <email>dr.jingxiang@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Zhou</last_name>
    <phone>02284118101</phone>
    <phone_ext>+86</phone_ext>
    <email>zhouyan2626@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Third Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300170</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Jing, MD</last_name>
      <phone>02284112323</phone>
      <phone_ext>+86</phone_ext>
      <email>dr.jingxiang@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://linkinghub.elsevier.com/retrieve/pii/S0168-8278(19)30034-0</url>
    <description>HCC diagnosis guideline</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491694/</url>
    <description>HCC diagnosis guideline</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/abs/pii/S0301562907005662</url>
    <description>Sonazoid contrast agent</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/abs/pii/S0301562906018023</url>
    <description>Sonazoid contrast agent</description>
  </link>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/abs/10.1002/jum.14940</url>
    <description>CEUS contrast agents</description>
  </link>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21338</url>
    <description>Cancer statistics in China</description>
  </link>
  <link>
    <url>https://link.springer.com/article/10.1007/s00330-010-2030-1</url>
    <description>EOB-MRI</description>
  </link>
  <reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. Corrigendum to &quot;EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma&quot; [J Hepatol 69 (2018) 182-236]. J Hepatol. 2019 Apr;70(4):817. doi: 10.1016/j.jhep.2019.01.020. Epub 2019 Feb 7.</citation>
    <PMID>30739718</PMID>
  </reference>
  <reference>
    <citation>Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15. Review.</citation>
    <PMID>28620797</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Sonazoid Contrast-enhanced ultrasound</keyword>
  <keyword>EOB-MRI</keyword>
  <keyword>Diagnostic Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

